Market Overview

UPDATE: Canaccord Genuity Initiates Synergy Pharmaceuticals at Buy on Opportunities

Share:
Related SGYP
What Synergy's New Patents Mean For Its Commercial Prospects
12 Biggest Mid-Day Losers For Thursday

Canaccord Genuity initiated coverage on Synergy Pharmaceuticals (NASDAQ: SGYP) with a Buy rating and a $7 price target.

Canaccord Genuity commented, "We see clear unmet need for the large proportion of chronic constipation patients non-responsive to current therapies and the smaller proportion that experience severe diarrhea with linaclotide (Linzess). Compared to recently approved Linzess (Forest/Ironwood), plecanatide may have better tolerability, with no diarrhea signal seen in Phase 2a. Data from the Phase 2b/3 trial is due by YE12, and if safety continues to be clean we expect wide use in severe chronic constipation, noting the market for severe idiopathic constipation may be limited."

Synergy Pharmaceuticals closed at $3.67 on Tuesday.

Latest Ratings for SGYP

DateFirmActionFromTo
Apr 2017CitigroupDowngradesNeutralSell
Jan 2017OppenheimerInitiates Coverage OnOutperform
May 2016Rodman & RenshawMaintainsBuy

View More Analyst Ratings for SGYP
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (SGYP)

View Comments and Join the Discussion!